Trials / Terminated
TerminatedNCT05343949
High Intensity Interval Training and Technologies in COPD
Promoting Activity in Chronic Obstructive Pulmonary Disease (COPD): Optimising High Intensity Interval Training and Technologies, a Pilot Study
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Hull University Teaching Hospitals NHS Trust · Other Government
- Sex
- All
- Age
- 30 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
Trials in COPD have shown that HIIT leads to the same positive outcomes as constant load training but causes less breathlessness and leg discomfort during training. However, HIIT protocols in existing trials have all been different and use relatively long interval durations (30 s) and short rests. This is sub-optimal because long interval durations lead to greater breathlessness and patients may fear that they will not fully recover during short rests, potentially decreasing adherence. A novel HIIT protocol involving very brief intervals (e.g. 10 s) with longer rests may provide the same benefits with less distress due to breathlessness.
Detailed description
Chronic Obstructive Pulmonary Disease (COPD) is a common and disabling smoking-related lung disease that is predicted to become the 3rd leading cause of death world-wide by 2030 (WHO, 2017). The economic burden of COPD in the United Kingdom is estimated by the British Lung Foundation (BLF) to be around £48.5 billion per year - higher than all other respiratory diseases, including lung cancer. Although widespread, Hull is a COPD 'hot spot' (BLF), with prevalence and mortality rates 36% and 75% higher than the national average, respectively. COPD is characterised by symptoms of breathlessness and cough that typically progress over time. As a consequence of these symptoms, physical activity (PA) is reduced in COPD patients, with lower levels associated with higher symptom burden, hospital admissions and mortality. Breathlessness is the most commonly reported barrier to PA in COPD, resulting in a cycle of deconditioning that ultimately leads to greater breathlessness and disability. Pulmonary rehabilitation (PR) improves symptoms and increases exercise capacity in COPD but uptake and adherence are poor. Patients with greater breathlessness are less likely to complete PR programmes which is unsurprising given that exercise-induced breathlessness can be distressing in COPD. One potential solution is high-intensity interval training (HIIT). HIIT involves short bursts of high-intensity exercise interspersed with periods of rest. The short duration of high-intensity exercise can reduce distressing breathlessness during exercise in COPD, mitigating the most common barrier to exercise. As mentioned above, PR participants benefit from increased exercise capacity. However, what patients can do (exercise capacity) does not always translate into what patients do (PA) and the effect of PR on PA has been disappointing. Interventions that aim to improve PA in COPD patients have been trialed, but the quality of evidence is low and results inconsistent. Physical inactivity is the strongest predictor of mortality in COPD patients and therefore, effective interventions that increase PA are desperately needed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | HIIT exercise program ABC | Delivery of 3 different exercise programs to patients with COPD to determine which program gives least breathlessness with the same exercise benefits |
| OTHER | HIIT exercise program CAB | Delivery of 3 different exercise programs to patients with COPD to determine which program gives least breathlessness with the same exercise benefits |
| OTHER | HIIT exercise program BCA | Delivery of 3 different exercise programs to patients with COPD to determine which program gives least breathlessness with the same exercise benefits |
Timeline
- Start date
- 2019-05-08
- Primary completion
- 2022-11-25
- Completion
- 2022-11-25
- First posted
- 2022-04-25
- Last updated
- 2024-04-11
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT05343949. Inclusion in this directory is not an endorsement.